Orforglipron

Orforglipron (development codes LY3502970 and OWL833, marketed as Foundayo) is an orally administered GLP-1 receptor agonist developed by Eli Lilly. It occupies an unusual position in a field otherwise built entirely on peptides: it produces GLP-1-like effects without being a GLP-1 analogue in any structural sense. Readers who arrive here from a guide on semaglutide or tirzepatide should understand that distinction first, because almost everything practical about orforglipron follows from it.

A peptide is a chain of amino acids joined by peptide bonds. Semaglutide, liraglutide, tirzepatide and retatrutide are all peptides: long, modified analogues of the natural incretin hormones. Orforglipron is not. It is a fully synthetic small molecule, a highly functionalized polycyclic heterocycle with the molecular formula C₄₈H₄₈F₂N₁₀O₅ and a molecular weight of roughly 883 g/mol. For comparison, semaglutide weighs more than 4,100 g/mol and is built on a 31-amino-acid backbone. Orforglipron has no amino acid sequence to report, no peptide bonds and no side chain designed to bind albumin.

That difference is not a technicality. Peptides are substrates for the proteases that line the digestive tract, and they are large and hydrophilic enough that intestinal absorption is poor. This is why the incretin class was injectable for two decades, and why the one peptide that did reach tablet form, oral semaglutide, needed a co-formulated absorption enhancer to get there. A small molecule such as orforglipron faces neither problem: it is chemically stable in gastric acid, it is not cleaved by proteolytic enzymes, and it crosses the intestinal wall on its own.

The practical consequence is a once-daily tablet with an ordinary pharmacokinetic profile rather than a fragile one. It also means orforglipron can be manufactured by conventional chemical synthesis rather than by the more constrained processes used for peptide drugs, which is one reason analysts have discussed it in terms of manufacturing scale. This guide describes what has been published, not what the drug might become.

Educational note: this article is for information only. It does not provide dosing instructions or a usage protocol, and it is not a substitute for advice from a qualified healthcare professional.

The GLP-1 receptor belongs to the class B family of G-protein-coupled receptors. These receptors evolved to bind long peptide hormones that wrap into an extended binding groove, which is precisely why pharmacologists long assumed that small molecules could not activate them effectively. Orforglipron is one of the compounds that overturned that assumption.

Structural work published on the compound describes it binding in a pocket located in the upper helical bundle of the receptor, involving both the extracellular domain and the transmembrane helices. This is not the site occupied by the native hormone, and the resulting receptor conformation differs from the one produced by GLP-1 itself. If you want the background physiology of the receptor and its natural ligand, the GLP-1 guide covers it in detail.

The signalling consequence is what pharmacologists call biased partial agonism. Orforglipron preferentially drives the Gs-coupled pathway that raises intracellular cyclic AMP, while recruiting relatively little beta-arrestin and causing less receptor internalization than a full peptide agonist would. In simple terms, it pushes hard on the signalling arm associated with insulin secretion and appetite regulation, and lightly on the arm associated with receptor desensitization. Whether that profile translates into a meaningful clinical difference compared with peptide agonists has not been established by head-to-head trials against injectable comparators in obesity.

Downstream, the pharmacology looks familiar to anyone who has read about the class: glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon release, slowed gastric emptying and reduced appetite through central GLP-1 receptor populations. The general mechanism is the same one described in our overview of GLP-1 receptor agonists.

Pharmacokinetically, phase 1 work in healthy participants reported peak plasma concentrations a few hours after dosing and a half-life long enough to support once-daily administration at steady state. That long exposure profile, combined with acid stability, is what makes a simple daily tablet workable.

This is the point most often misunderstood, so it deserves a section of its own. Oral semaglutide and orforglipron are both tablets, but they solve the oral-delivery problem in completely different ways.

Oral semaglutide is the peptide semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, known as SNAC. SNAC transiently raises local pH in the stomach and promotes absorption of the peptide across the gastric mucosa. The mechanism works, but it is narrow: absorption is highly sensitive to the volume of fluid in the stomach and to the presence of food. That is why the approved labelling for semaglutide tablets requires them to be taken on an empty stomach in the morning with no more than about 120 mL (4 fluid ounces) of plain water, swallowed whole, with a wait of at least 30 minutes before eating, drinking anything else or taking other oral medicines. Even with those precautions, oral bioavailability of the peptide remains low and variable between individuals.

Orforglipron does not need an absorption enhancer at all, because there is no fragile peptide to protect. Eli Lilly's approval announcement described Foundayo as a GLP-1 pill that can be taken at any time of day without food or water restrictions, and the UK MHRA made the same point when it authorized the product. From the user's perspective, that removes a daily scheduling constraint that is a known source of dosing errors and inconsistent absorption with peptide tablets.

It is worth being precise about what this does and does not mean. Removing food and water restrictions is a convenience and consistency advantage, not an efficacy claim. It does not make orforglipron safer, it does not make gastrointestinal side effects less likely, and it does not mean the drug can be taken casually. Orforglipron is a prescription medicine with a required titration schedule, contraindications and monitoring requirements that only a prescriber can apply to an individual.

Readers comparing tablet and injectable options may also find our overview of alternatives to Ozempic useful for context on how these products differ in route, schedule and evidence base.

Two phase 2 trials published in 2023 set the expectations that the phase 3 programme later tested. They are worth reading because their results are frequently quoted out of context.

The first, published in The New England Journal of Medicine in September 2023 by Wharton and colleagues, was a randomized, double-blind, placebo-controlled dose-finding study in adults with obesity, or with overweight plus at least one weight-related condition, and without diabetes. At week 36, a weight reduction of at least 10% was achieved by 46% to 75% of participants across the orforglipron dose groups, compared with 9% of those on placebo. The company reported mean weight reduction of up to 14.7% at 36 weeks in this trial. Two points matter here: the trial was a phase 2 study of a few hundred participants, and 36 weeks is short for a weight-management endpoint that is usually assessed at 68 to 72 weeks.

The second, published in The Lancet in 2023 by Frias and colleagues, was a 26-week multicentre dose-response study in 383 randomized participants with type 2 diabetes, using both placebo and injectable dulaglutide as comparators. At week 26, mean HbA1c change with orforglipron reached up to a reduction of 2.10% (1.67% placebo-adjusted), versus 0.43% with placebo and 1.10% with dulaglutide. Doses of 12 mg and above produced significant reductions in both HbA1c and body weight relative to placebo and to dulaglutide.

Phase 2 results in this class have historically been optimistic relative to phase 3, partly because early trials enrol smaller, more selected populations and use shorter follow-up. That is exactly what happened here: the phase 3 obesity results, described below, were more modest than the phase 2 headline figures. Anyone citing the 14.7% number should be clear that it comes from a 36-week phase 2 study and not from the pivotal trials.

A phase 1a single- and multiple-ascending-dose study in healthy participants, published in Diabetes, Obesity and Metabolism, provided the underlying pharmacokinetic and tolerability data that supported once-daily dosing.

The pivotal obesity evidence comes from the ATTAIN programme. ATTAIN-1, published in The New England Journal of Medicine in 2025, was a multinational, randomized, double-blind, placebo-controlled phase 3 trial in 3,127 adults with obesity and without diabetes, treated for 72 weeks with once-daily orforglipron at 6 mg, 12 mg or 36 mg, or placebo, alongside diet and physical activity.

Under the treatment-regimen estimand reported in the published paper, the mean change in body weight from baseline to week 72 was a reduction of 7.5% with 6 mg, 8.4% with 12 mg and 11.2% with 36 mg, compared with 2.1% with placebo. In the 36 mg group, 54.6% of participants achieved a weight reduction of at least 10%, versus 12.9% on placebo. Eli Lilly's press communication cited a figure of 12.4% for the highest dose. That number reflects a different analysis (the efficacy estimand, which estimates the effect if treatment is taken as assigned) and is not interchangeable with the 11.2% published figure. Both are legitimate, and citing them as if they were the same result is a common error.

ATTAIN-2, published in The Lancet in December 2025, studied the harder population: adults with obesity or overweight and type 2 diabetes, randomized across 136 sites in ten countries. At week 72, mean bodyweight change under the treatment-regimen estimand was a reduction of 5.1% with 6 mg, 7.0% with 12 mg and 9.6% with 36 mg, versus 2.5% with placebo. HbA1c fell by 1.22% to 1.66% with orforglipron versus 0.47% with placebo. The smaller weight effect in people with type 2 diabetes is a consistent finding across the incretin class, not something specific to orforglipron.

A phase 3b trial, ATTAIN-MAINTAIN, published in Nature Medicine in 2026, asked a different question: can people who lost weight on an injectable maintain it after switching to the oral small molecule? Participants previously treated with tirzepatide or semaglutide in SURMOUNT-5 were randomized to orforglipron or placebo for 52 weeks. Most of the prior weight reduction was maintained on orforglipron, with a larger gap for those switching from tirzepatide than from semaglutide, which the investigators linked to tirzepatide's dual receptor mechanism.

The diabetes evidence comes from the ACHIEVE programme. ACHIEVE-1, published in The New England Journal of Medicine in September 2025, was a 40-week randomized, double-blind, placebo-controlled trial in 559 adults with early type 2 diabetes inadequately controlled by diet and exercise alone.

At week 40, the mean HbA1c across orforglipron dose groups was 6.5% to 6.7%, a clinically meaningful reduction from baseline and significantly better than placebo. The percent change in body weight from baseline to week 40 was a reduction of 4.5% with the 3 mg dose, 5.8% with 12 mg and 7.6% with 36 mg, versus 1.7% with placebo. Reported discontinuation rates due to adverse events were in the region of 4% to 8% on orforglipron compared with about 1% on placebo, and no severe hypoglycaemia was reported, which is expected given the glucose-dependent mechanism of GLP-1 receptor agonism.

A larger and longer trial, ACHIEVE-4, compared orforglipron with insulin glargine in more than 2,700 participants with type 2 diabetes at elevated cardiovascular risk, with a minimum treatment period of about 52 weeks and follow-up extending to 104 weeks. The sponsor reported that the trial met its primary objective of non-inferiority for major adverse cardiovascular events versus insulin glargine, alongside greater reductions in HbA1c and body weight. Results were presented at scientific meetings in 2026. At the time of writing we could not confirm a peer-reviewed publication of the full ACHIEVE-4 dataset, so those figures should be treated as sponsor-reported and preliminary until the complete paper is available.

Taken together, the diabetes data position orforglipron as an oral agent with glycaemic efficacy in the range expected of GLP-1 receptor agonists, with the weight reduction that typically accompanies the class. Cross-trial comparisons with injectable agents are not a substitute for head-to-head evidence, and the published trials above used placebo or a non-GLP-1 comparator, not the most potent injectables.

The tolerability profile of orforglipron is, in the words of the trial reports, consistent with the GLP-1 receptor agonist class. Gastrointestinal adverse events dominate, they are mostly mild to moderate, and they cluster during the dose-escalation phase rather than persisting at steady state.

In ATTAIN-1, the published safety data show adverse events leading to treatment discontinuation in 5.3% to 10.3% of participants across the orforglipron dose groups, compared with 2.7% on placebo, with the highest rate in the 36 mg group. Nausea, vomiting, diarrhoea and constipation were the most frequently reported events, and reported rates rose with dose. In ACHIEVE-1, discontinuation for adverse events was lower, in the region of 4% to 8% versus about 1% on placebo, consistent with the lower doses and shorter 40-week exposure in that trial.

Class-level warnings apply to orforglipron as they do to every GLP-1 receptor agonist. These include the risk of pancreatitis, gallbladder disease, dehydration related to gastrointestinal losses, potential worsening of diabetic retinopathy in some settings, and the rodent thyroid C-cell tumour signal that underpins the class contraindication in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Loss of lean body mass with rapid weight reduction is an active area of research across the whole class. Our article on GLP-1 side effects covers these in more depth.

Early work raised questions about liver enzyme elevations with some non-peptide GLP-1 agonists, a signal that contributed to the discontinuation of a competing oral candidate. Across the orforglipron phase 3 trials the sponsor has reported no hepatic safety signal of that kind, but hepatic monitoring remains part of the regulatory discussion for this chemical class, and long-term post-marketing surveillance is the appropriate place to settle it.

Important: this section describes reported trial findings. It is not a list of everything that can happen, and it is not a basis for self-assessment. Anyone experiencing adverse effects on any GLP-1 medicine should contact their prescriber.

The table below sets out the structural, practical and regulatory differences between the main options. The efficacy figures come from separate trials with different populations, durations and endpoints, so they are not head-to-head comparisons and should not be read as a ranking.

Three caveats matter more than the numbers. First, estimands differ between trials, and a trial reporting the efficacy estimand will always produce a larger figure than the same trial reporting the treatment-regimen estimand. Second, baseline populations differ: ATTAIN-2 enrolled people with type 2 diabetes, who reliably lose less weight than people without. Third, only a direct randomized comparison can rank two drugs, and no such trial between orforglipron and the leading injectables in obesity had been published at the time of writing.

For a broader view of where these agents sit relative to newer multi-receptor candidates, see our overview of the next generation of incretin therapies.

Regulatory status changes quickly in this field, so the following reflects what could be verified as of September 30, 2026, and readers should check current regulator websites before relying on it.

In the United States, the FDA approved orforglipron on April 1, 2026 under the brand name Foundayo, indicated together with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or adults with overweight and at least one weight-related condition. Eli Lilly's announcement described it as the first oral small-molecule GLP-1 receptor agonist approved for chronic weight management and emphasised that it can be taken at any time of day without food or water restrictions. The company has stated that a submission for a type 2 diabetes indication was filed in 2026; that indication was not approved in the United States at the time of writing.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency authorized orforglipron on August 10, 2026, making the UK the first country in Europe to do so. The UK authorization covers weight management in adults meeting defined BMI criteria and also extends to improving glycaemic control in adults with insufficiently controlled type 2 diabetes. Authorization is not the same as funded availability: at the time of the announcement the product was not available through the NHS.

In the European Union, orforglipron was under evaluation by the European Medicines Agency, appearing on CHMP agendas during 2026. A centralised EU marketing authorization had not been confirmed at the time of writing. Availability, reimbursement status and legal classification vary by country, and a product approved in one jurisdiction may be unapproved or unavailable in another.

One consequence of approval deserves a plain statement: orforglipron is a prescription medicine. Material sold online as unapproved research-grade orforglipron sits outside any regulatory framework for identity, purity or dosage accuracy, and nothing in this guide should be read as encouragement to obtain or use it outside a prescribed, supervised context.

Even with a phase 3 programme and two regulatory authorizations behind it, several important questions about orforglipron remain open.

Long-term outcomes. The published obesity trials ran for 72 weeks and the main diabetes trial for 40 weeks. ACHIEVE-4 extended cardiovascular follow-up further and reported non-inferiority versus insulin glargine, but a dedicated cardiovascular outcomes trial in people with obesity and established cardiovascular disease or chronic kidney disease was still under way at the time of writing. Whether the mortality and event-rate signals reported so far hold up under full adjudication and multiplicity control is not yet settled.

Head-to-head efficacy. No published randomized trial directly compares orforglipron with injectable semaglutide or tirzepatide for weight reduction. Indirect comparison suggests orforglipron sits below the most potent injectables on mean weight change, but indirect comparisons are unreliable when populations and estimands differ. ATTAIN-MAINTAIN provides the most informative signal so far, and it showed some loss of effect among people switching down from tirzepatide.

Durability and discontinuation. As with every agent in this class, weight regain after stopping is the expected pattern, and the maintenance data cover 52 weeks rather than years. Whether an oral option changes real-world persistence, which is poor across the class, is an open empirical question rather than a settled advantage.

Special populations and interactions. Orforglipron is cleared largely by hepatic metabolism with CYP3A involvement, which raises drug-interaction questions that matter for people on multiple medications. Data in pregnancy, in adolescents, in advanced renal or hepatic impairment, and in older adults with frailty remain limited, with subgroup analyses in people aged 65 and over only beginning to appear.

Medical disclaimer: this guide is for educational purposes only and does not constitute medical advice, a treatment recommendation or a dosing protocol. Orforglipron is a prescription medicine where approved, its availability and legal status vary by jurisdiction, and decisions about its use should be made only with a qualified healthcare professional who knows your medical history.